Selskabets formål er at drive virksomhed, herunder produktion, udvikling og kommercialisering af analytisk laboratoriumudstyr, herunder instrumenter, reagenser, software og services, samt al virksomhed, som efter direktionens skøn er beslægtet hermed, herunder indgåelse af salgs-, service-, leje-, leasing- og andre aftaler.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 35.5 mio. | 3.3 mio. | 60.7 mio. | 55.2 mio. | 0 | |
CVR: 31088798
Previous names: KR 1501 ApS, BECKMAN COULTER DENMARK ApS
Jose Antonio Alba Gonzalez joined as director
Shiung-Jin Yong left as director
Antonio Roberto Filho De Godoy left as director
Companies in the same industry and area
CVR 46279921
CVR 45569233
CVR 45203093
CVR 30652444
CVR 39877929
Compared to 52 companies in Fremstilling af bestrålingsudstyr og elektromedicinsk og elektroterapeutisk udstyr
Comparison is based on industry median values
The financial health of BECKMAN COULTER DANMARK ApS appears to be declining, with a significant drop in revenue from 59.4 million DKK in 2022 to 35.5 million DKK in 2024. Despite this downturn, the company has managed to maintain profitability, reporting a profit of 3.3 million DKK in 2024, up from 3.1 million DKK in 2023. Equity has shown a positive trend, increasing from 48.8 million DKK in 2022 to 55.2 million DKK in 2024, indicating a strengthening balance sheet. However, the substantial decrease in revenue raises concerns about its market position and overall stability within the medical equipment manufacturing industry.
AI-generated summary
companydata.dk